Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
J Med Vasc ; 46(5-6): 215-223, 2021.
Article in English | MEDLINE | ID: mdl-34862015

ABSTRACT

INTRODUCTION: Treatment of cancer-associated thrombosis (CAT) requires specific approaches, although it is well codified in most cases. Current national and international (International Initiative on Cancer and Thrombosis, ITAC) Clinical Practice Guidelines (CPG) recommend the use of low-molecular-weight heparin (LMWH) over 6 months as first treatment option, and anticoagulation should be maintained thereafter as long as cancer is active. Since compliance improves when patients understand their disease and related treatments, we created a dedicated patient education program (PEP) for CAT, aiming to improve quality of care. METHODS: Retrospective analysis of all patients who voluntarily joined the PEP for CAT from 2014 to 2020. RESULTS: In total, 182 cancer patients (median age, 64.9 years) were included, 53.3% with metastatic disease. A total of 528 PEP sessions (median, 3 per patient) were delivered. After PEP completion, the rate of self-injections or those performed at home by a relative had increased from 49.1% to 59.8% (P=0.05). Quality of life had improved significantly (P=0.025) and 90.0% of patients reported adhering to anticoagulant therapy. CONCLUSION: Implementation of a structured and personalized PEP for CAT is feasible, allowing to improve cancer patient empowerment, adherence to CAT treatment and quality of life. The Groupe francophone et cancer (GFTC) members aim at facilitating access to CAT-PEP for both patients and caregivers and use of the multi-language ITAC-CPG mobile app (free access: www.itaccme.com) to improve the care and quality of life of patients with CAT.


Subject(s)
Neoplasms , Thrombosis , Heparin, Low-Molecular-Weight , Humans , Neoplasms/complications , Patient Education as Topic , Quality of Life , Retrospective Studies , Thrombosis/drug therapy , Thrombosis/etiology
2.
J Med Vasc ; 45(1): 28-40, 2020 Feb.
Article in English | MEDLINE | ID: mdl-32057323

ABSTRACT

Venous thromboembolism (VTE) is a common disease complication in cancer patients and the second cause of death after cancer progression. VTE management and prophylaxis are critical in cancer patients, but effective therapy can be challenging because these patients are at higher risk of VTE recurrence and bleeding under anticoagulant treatment. Numerous published studies report inconsistent implementation of existing evidence-based clinical practice guidelines (CPG), including underutilization of thromboprophylaxis, and wide variability in clinical practice patterns across different countries and various practitioners. This review aims to summarize the 2019 ITAC-CME evidence-based CPGs for treatment and prophylaxis of cancer-related VTE, which include recommendations on the use of direct oral anticoagulants specifically in cancer patients. The guidelines underscore the gravity of developing VTE in cancer and recommend the best approaches for treating and preventing cancer-associated VTE, while minimizing unnecessary or over-treatment. Greater adherence to the 2019 ITAC guidelines could substantially decrease the burden of VTE and improve survival of cancer patients.


Subject(s)
Anticoagulants/administration & dosage , Neoplasms/complications , Practice Guidelines as Topic/standards , Venous Thromboembolism/drug therapy , Administration, Oral , Anticoagulants/adverse effects , Consensus , Guideline Adherence/standards , Hemorrhage/chemically induced , Humans , Neoplasms/blood , Neoplasms/diagnosis , Recurrence , Risk Factors , Societies, Medical/standards , Treatment Outcome , Venous Thromboembolism/blood , Venous Thromboembolism/diagnosis , Venous Thromboembolism/etiology
3.
Bull Soc Pathol Exot ; 94(3): 231-4, 2001 Aug.
Article in French | MEDLINE | ID: mdl-11681216

ABSTRACT

HHV8 was discovered in 1994 and few studies on this virus have been conducted in Africa. The virus is related to Kaposi sarcoma, an opportunistic affection occurring during HIV infection. No studies have been carried out on this subject in Senegal, a country known for its low KS prevalence even among people living with HIV/AIDS. Thus it will be interesting to explore this field. The aim of our study has been first, to demonstrate the presence of HHV8; second, to evaluate sero-prevalence of the infection in Senegal and third, to determine the specificities of HHV8 infection in our country. We performed our study on 407 pregnant women whose average age was 29.24 years, the majority of whom were Senegalese. HIV serology was done by dot blot for the screening and western blot for the confirmation. For the diagnosis of HHV8 infection, we used the indirect immunofluorescence kit of ABI. HIV infection was low among this study population; 0.5% and no HIV1 infection was mentioned. Among the 407 women, 58 or 14.3% were HHV8 positive and there was no HHV8/HIVco-infection. Regarding marital status, no significant difference was found between HHV8 positive and HHV8 negative among unmarried, monogamous or polygamous women. However, women having had 4 to 5 children were more likely to test positive for HHV8. The difference is significant and a relationship has been established with a p value of 0.02. Regarding pregnancy, HHV8 infection is more closely related to abortion: 17.2% of women who had aborted were HHV8 positive versus 4.9% seronegative. The odds ratio calculation shows a strong correlation with a p value of 0.01. No correlation was found between HHV8 infection of the mother and neonate mortality or Apgar score. However, a relationship did show up between HHV8 infection of the mother and low birth weight. 29.2% of seropositive women had had a child with a birth weight under 2600 g whereas only 16.3% of seronegative women had had babies with low birth weight. We determined that HHV8 is indeed present in Senegal. Further studies should focus on transmission routes as well as the molecular epidemiology of this virus and diseases related to HHV8 infection in Senegal.


Subject(s)
Herpesviridae Infections/diagnosis , Herpesviridae Infections/epidemiology , Herpesvirus 8, Human , Pregnancy Complications, Infectious/virology , Abortion, Spontaneous/virology , Adult , Antibodies, Viral/blood , Female , Fluorescent Antibody Technique, Indirect , Gestational Age , HIV Seropositivity , Herpesviridae Infections/transmission , Herpesvirus 8, Human/immunology , Humans , Infant Mortality , Infant, Low Birth Weight , Infant, Newborn , Infectious Disease Transmission, Vertical , Pregnancy , Senegal/epidemiology
4.
Dakar Med ; 44(1): 28-31, 1999.
Article in French | MEDLINE | ID: mdl-10797982

ABSTRACT

Pneumocystosis is an opportunist parasitic disease which occurs currently at Europe and United States in HIV infected patients. In Africa, the disease is not current. Pneumocystosis has been detected in the Fann medical universitary center at Dakar from HIV infected patients with acido alcoholo resistant bacilli negative pneumopathy. Analysis of broncho alveolar liquid(BAL) of 29 patients after Giemsa and Blue of Toluidin O staining allowed isolating of two cases of pneumocystosis. A man and a woman were the patients. They were HIV1 positive with at X ray bilateral interstitial syndrome. The CD4 lymphocytes count of the one was lower than 200/mm3 and for the other it was higher than 200/mm3.


Subject(s)
Acquired Immunodeficiency Syndrome/complications , Pneumonia, Pneumocystis/diagnosis , Adult , Bronchoalveolar Lavage Fluid/microbiology , CD4 Lymphocyte Count , Female , Humans , Male , Middle Aged , Pneumocystis/isolation & purification , Pneumonia, Pneumocystis/complications , Pneumonia, Pneumocystis/microbiology , Senegal , Staining and Labeling
SELECTION OF CITATIONS
SEARCH DETAIL
...